The company popularizing at-home saliva kits just received a massive investment to further develop drugs based on user DNA.
23andMe, a genetics testing startup, announced on Tuesday it banked a $250 million funding round from Sequoia Capital. The Silicon Valley venture capitalist firm has backed companies like Google (GOOG), Instagram, and Airbnb.
The company is most known for collecting the spit of customers in exchange for information about their genetic history, health, and physical traits based on their DNA. In addition to helping consumers learn more about themselves, the company leverages that data for disease research and developing drug therapies.
The team is currently running research programs dedicated to a range of areas, like oncology, skin, and cardiovascular disease. It is leveraging its data to help academic and pharmaceutical partners develop new therapies for diseases like Parkinson’s, irritable bowel syndrome, and lupus. Read more